Physician profile
Scott Gold
NPI 1578522058
$189,103.78
in general payments reported to CMS, 2019-2025
53 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $81K · 2020: $34K · 2021: $44K · 2022: $26K · 2023: $1,114 · 2024: $2,271 · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821 · Consulting Fee: $1,838 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.56 |
| Consulting Fee | $1,838.00 |
| Education | $132.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $50,263.73 | 2019-2025 | |
| Emd Serono, INC. | $42,675.69 | 2019-2025 | Mavenclad, Mavenclad |
| Biogen, INC. | $40,137.97 | 2019-2025 | Tysabri, Vumerity |
| Genentech USA, INC. | $25,873.67 | 2019-2024 | Ocrevus, Ocrevus Zunovo |
| E.R. Squibb & Sons, L.L.C. | $11,465.40 | 2020-2022 | |
| Celgene Corporation | $8,114.69 | 2019-2023 | Zeposia |
| Novartis Pharmaceuticals Corporation | $2,875.41 | 2019-2022 | |
| Tg Therapeutics, INC. | $2,241.47 | 2023-2025 | |
| Abbvie INC. | $671.91 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $412.63 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $354.80 | 2019-2023 | Austedo |
| Amgen INC. | $270.21 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $269.13 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $245.01 | 2019-2020 | |
| Ucb, INC. | $214.69 | 2019-2023 | Briviact |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Gold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.